Pharmacokinetic Study of Aerosolized Colimycin in Cystic Fibrosis
Overview
Pharmacokinetics of colimycin will be assessed during 12 hours after administration of 2M UI colimycin either as an aerosol or after IV injection, the administration being separated by 5 to 10 days intervals
Study Type
- Study Type: Interventional
- Study Primary Completion Date: February 2013
Interventions
- Drug: COLIMYCINE inhalation
- 2 MILLION UI
- Drug: COLIMYCINE injectable
- 2 MILLIONS UI
Arms, Groups and Cohorts
- Experimental: COLIMYCINE injectable
- Experimental: COLIMYCINE inhalation
Participating in This Clinical Trial
Inclusion Criteria
- Males and females, adults. – Suffering from stable cystic fibrosis – Colonized by P. aeruginosa – Having given informed consent. – Able to follow the protocol – Having a social insurance Exclusion Criteria:
- Renal insufficiency – Allergy to colistin or polymixins – Myasthenia – Recent severe hemoptysis – Liver cirrhosis and hepatic insufficiency – Hypoalbuminemia – Colonization by Burkholderia cepaea or Stenotrophomonas maltophilin – Pregnancy
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Investigator Details
- Lead Sponsor
- Poitiers University Hospital
- Provider of Information About this Clinical Study
- Sponsor
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.